MaaT034, a ground-breaking full ecosystem synthetic microbiota product, is the first candidate coming from the Company's MET-C platform. Produced using a co-culturing technology and for large scale manufacturing, MaaT034 is being developed to improve responses to immunotherapy for patients with solid tumors in combination with an ICI (Immune Checkpoint Inhibitors) treatment. The first-in-human study is planned for 2025, with clinical batches currently being produced in 2024.
The Company will detail the new preclinical data in a press release on
AACR Poster Presentation details
Title: Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors
Session Category: Immunology
Session Title: Microbiome, Inflammation, and Cancer
Session Date and Time:
Location: Poster Section 2
Poster Board Number: 18
Published Abstract Number: 6687
About
Forward-looking Statements
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
Contact:
Tel: 04 28 29 14 00
(C) 2024 Electronic News Publishing, source